

June 30, 2017

Dear AmeriHealth Caritas Louisiana Provider,


AmeriHealth Caritas Louisiana wants to make you aware that the Louisiana Department of Health (LDH) is partnering with medical malpractice insurance provider, LAMMICO, in an effort to reduce Louisiana's high preterm birth rate through increased utilization of 17 alpha-hydroxyprogesterone caproate (17P) among women with a prior preterm, singleton, spontaneous delivery. LAMMICO is providing **FREE** CME/CE credit for online educational activities for all providers and their nursing staff.

The use of progesterone to reduce preterm birth in appropriate candidates is no longer investigational: early identification of medically eligible women and treatment with progesterone has been proven to **reduce preterm births by 33%**.¹

Due to the complex nature of 17P administration, you may feel that undue burden is placed on your shoulders to ensure proper implementation of an injection plan. A solution that may be lesser known in the perinatal care community is **17P home administration – a covered benefit available through AmeriHealth Caritas Louisiana**. Additionally, our RN Case Managers are available to help members who are scheduled to receive 17P administration in the physician offices, by scheduling patient transportation, conducting reminder calls, and providing patient education.

LAMMICO also presents free access for all providers and their nursing staff to the ***“Progesterone Use for Preventing Preterm Births”*** monograph. This is eligible for CME and CE credit and MOC credit by ABFM. For those currently insured by LAMMICO, it can contribute toward 2 RM credits required to earn a 10% per-provider discount on basic limits of your LAMMICO premium. Additional information and resources are available at www.medicalinteractive.com/cart/product-detail.php?id=181 and for nurses please go to: www.medicalinteractive.com/cart/product-detail.php?id=180.

Sincerely,



Rodney Wise, M.D., FACOG
Market Medical Executive

¹ Meis, P. (2003, June 12). Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate. *The New England Journal of Medicine*. Retrieved from <http://www.nejm.org/doi/full/10.1056/NEJMoa035140#t=article>